Skip to main content

Advertisement

Table 2 Individuals responding to candidate antigens from clinical cohorts in Turkey and Ethiopia

From: Development of a proof of concept immunochromatographic lateral flow assay for point of care diagnosis of Mycobacterium tuberculosis

Results from Turkish clinical cohorts
Cohort Clinical definition Number (percentage) responding to antigen
   ESAT-6 CFP8A Acr: MPT83 ORF3 Any antigen
TB patients (n = 99) Pulmonary (n = 91) 17 (18.6%) 9 (9.8%) 40 (43.9%) 5 (5.5%) 45 (45.5%)
  Extra-pulmonary (n = 8) 0 (0%) 0 (0%) 2 (25%) 0 (0%) 2 (25%)
TB contacts (n = 48) PPD+, known exposure (n = 48) 4 (8.5%) 2 (4.2%) 16 (33.3%) 2 (4.2%) 18 (37.5%)
Community controls (n = 153) Symptomatic, non-TB (n = 8) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
  Healthy, no identified exposure (n = 145) 6 (4.2%) 2 (1.4%) 15 (9.1%) 1 (0.7%) 18 (11.8%)
Results from Ethiopian clinical cohorts
Cohort Clinical definition Number (percentage) responding to antigen
   ESAT-6 CFP8A Acr: MPT83 ORF3 Any antigen
TB patients (n = 79) Pulmonary (n = 48) 9 (18.8%) 5 (10.4%) 24 (50.0%) 0 (0%) 26 (54.2%)
  Extra-pulmonary (n = 31) 4 (12.9%) 2 (0.65%) 12 (38.7%) 0 (0%) 12 (38.7%)
TB contacts (n = 73) Known exposure (n = 73) 4 (8.48%) 2 (4.16%) 19 (26.0%) 0 (0%) 21 (28.8%)
Community controls (n = 60) Healthy, no identified exposure (n = 60) 6 (4.19%) 2 (1.39%) 12 (20.0%) 0 (0%) 16 (26.7%)